Table 1.
Inhibition of HIV-1 replication in acutely infected cells by CDK9 kinase inhibitors
| Compound | IC50, μM
|
||
|---|---|---|---|
| CDK9 | Spread (H9) | Cytotoxicity (H9) | |
| DRB | 3.0 | 9.0 | 38 |
| T172298 | 0.9 | 2.5 | 38 |
| T276339 | 4.0 | 1.0 | 25 |
The IC50 of viral production in H9 human T lymphoid cells was determined as described (19). The cytotoxicity column shows the concentration of compound at which the first signs of cellular toxicity can be detected. Effects on cellular viability, growth, or morphology were scored as cytotoxic effects. The IC50 values of ribofuranosyl benzymidazole (DRB), benzymidazole (T172298), and isoxazole (T276239) in a CDK9 in vitro kinase assay have been published (4) and are included to facilitate comparison of the relative potency of these compounds in both assays.